K2M Expands Biologics Portfolio

In short

We’ve covered spinal company K2M, Inc., before, most recently in June when the company launched its pedicle screw size dedicated to people of smaller stature, here. This week comes the news that the company is announcing a major expansion of its U.S. biologics offering with the launch of VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems.

Background

K2M, Inc. specialises in research, development, and commercialisation of simplified solutions for the treatment of complex spinal pathologies and minimally invasive procedures. The company is a worldwide leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients.

VESUVIUS marks an entirely new family of products for K2M, designed specifically to enhance bone regeneration after spine surgery and in a variety of configurations and sizes to meet surgeons’ clinical needs.

K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity. VESUVIUS (pictured) Demineralised Fibres and Sponge are treated with LifeNet Health’s patented ALLOWASH XG® sterilisation process and PAD® demineralisation technology which the company says protects Bone Morphogenetic Proteins (BMPs), while ensuring optimal osteoinductivity.

K2M says the LifeNet Health relationship has enabled it to extend its existing VIKOS Cervical offering to include unicortical, tricortical, and iliac crest grafts, as well as add two new product lines, VIKOS Void Fillers and VIKOS Shafts. VIKOS has been designed specifically to enhance osteoconductivity after spine surgery and, in addition to LifeNet Health’s ALLOWASH XG® process, also features proprietary PRESERVON® technology for storage at ambient temperature.

Company comments

for K2M

According to Paul Savas, MD, K2M’s Medical Director for Tissue Products and orthopedic surgeon in Williamsburg, Virginia, “K2M’s launch of VESUVIUS and VIKOS products is an exciting expansion to their biologics portfolio. VESUVIUS and VIKOS provide useful alternatives to the management of complex spinal surgical issues, and these unique products complement and enhance K2M’s already comprehensive and innovative spine portfolio.”

“We are excited to further our relationship with LifeNet Health, a leader in the field, to dramatically grow our company’s presence in the $1.8 billion U.S. biologics sector and meet a significant demand for the high quality products that surgeons have come to expect from K2M,” stated Eric Major, K2M’s President and CEO.

for LifeNet 

“Our ability to save lives and restore health depends on the grace and generosity of donors and their families,” stated Doug Wilson, Executive Vice President of LifeNet Health. “We are fortunate to have available donations and we are honoring the gifts of donation and using them to their fullest extent. Launching these new biologic implants with K2M made sense because we were able to work with an organization with a record of enabling healthcare professionals around the world to help more people.”

Future pipeline

K2M says its product development pipeline includes spinal stabilisation systems, minimally invasive systems, biologics, and other advancing technologies such as motion preservation, annular repair, and nucleus replacement.

Source: K2M, Inc.